Pfizer raised the full-year sales forecast for its Covid-19 vaccine to $36 billion, as it has signed deals with countries for booster doses and received clearances for using its shots in children. Price has not reflected the existing drugs, pipelines of drugs, and what appears to be recurring revenue. The market is shifting to value stocks, companies that making real money and free cash flow. Pfizer can double the stock price from here easily with the leadership in vaccines and pills for COVID, and breakthroughs in other areas. It should buy back shares, pay a special dividend and raise prices.$Pfizer(PFE)$